A5072381949- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Genital Health and Disease
- Cervical Cancer and HPV Research
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Cytokine Signaling Pathways and Interactions
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Complement system in diseases
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Polyomavirus and related diseases
- Transgenic Plants and Applications
- CAR-T cell therapy research
- Long-Term Effects of COVID-19
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Biosensors and Analytical Detection
- Inflammasome and immune disorders
- Parvovirus B19 Infection Studies
Saarland University
2015-2025
Leibniz-Institute for New Materials
2024
Universitätsklinikum des Saarlandes
2020-2023
Institute of Virology of the Slovak Academy of Sciences
2018-2021
Kiel University
2009-2017
Clinical Research Center Kiel
2007-2015
University Hospital Schleswig-Holstein
2010-2014
University of Lübeck
2010-2014
Ab-dependent cellular cytotoxicity (ADCC) is usually considered an important mechanism of action for immunotherapy with human IgG1 but not IgG2 Abs. The epidermal growth factor receptor (EGF-R) Ab panitumumab represents the only approved and inhibition EGF-R signaling has been described as its principal action. In this study, we investigated effector mechanisms compared zalutumumab, isotype. Notably, was effective zalutumumab in recruiting ADCC by myeloid cells (i.e., neutrophils monocytes)...
Research Article5 August 2013Open Access IgA EGFR antibodies mediate tumour killing in vivo Peter Boross Immunotherapy Laboratory, Laboratory for Translational Immunology, UMC Utrecht, The Netherlands Search more papers by this author Stefan Lohse Division of Stem Cell Transplantation and Immunotherapy, Department Internal Medicine II, Christian-Albrechts-University, Kiel, Germany Maaike Nederend Johannes Hendrik Marco Jansen Geert van Tetering Michael Dechant IV, Nephrology Hypertension,...
Abstract The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis required understand the manifestation progression of COVID-19, monitor seroconversion within general population, support vaccine development. majority currently available commercial serological assays only quantify antibody against individual antigens, limiting our understanding response. To overcome this, we have developed multiplex immunoassay (MultiCoV-Ab) including spike nucleocapsid...
Abstract Neutrophils are the most abundant circulating FcR-expressing WBCs with potent cytotoxic ability. Currently, they recognized as promising effector cells for Ab-mediated immunotherapy of cancer, because their capacity to kill tumor is greatly enhanced by Ag-specific mAbs. The FcαRI represents FcR on neutrophils induction cell killing. However, mechanisms death that induced poorly understood. Because these can be used modulation anticancer treatment, we investigated neutrophil-mediated...
Abstract Dimeric IgA Abs contribute significantly to the humoral part of mucosal immune system. However, their potential as immunotherapeutic agent has hardly been explored. In this article, we describe production, purification, and functional evaluation recombinant dimeric against epidermal growth factor receptor. Human joining chain-containing was produced by nonadherent Chinese hamster ovarian (CHO)-K1 cells under serum-free conditions. Purification anti-human κ anti–His-tag affinity,...
The epidermal growth factor receptor (EGFR) is a widely expressed Ag that successfully targeted in tumor patients by mAbs or tyrosine kinase inhibitors. A clinical study non-small cell lung cancer demonstrated positive correlation between EGFR expression levels and the therapeutic efficacy of mAb cetuximab. However, impact on different mechanisms action (MoAs) triggered has not been defined. In this study, BHK-21 cells were stably transfected to express levels, which quantified...
Antibodies of IgA isotype effectively engage myeloid effector cells for cancer immunotherapy. Here, we describe preclinical studies with an Fc engineered IgA2m(1) antibody containing the variable regions EGFR cetuximab. Compared wild-type IgA2m(1), molecule lacked two N-glycosylation sites (N166 and N337), free cysteines (C311 C472), contained a stabilized heavy light chain linkage (P221R mutation). This novel displayed improved production rates biochemical properties compared IgA. In vitro,...
BackgroundThe extent to which children and adolescents contribute SARS-CoV-2 transmission remains not fully understood. Novel high-capacity testing methods may provide real-time epidemiological data in educational settings helping establish a rational approach prevent minimize transmission. We investigated whether pooling of samples for detection by RT-qPCR is sensitive feasible diagnostic strategy surveillance infections schools.MethodsIn this study, students school staff 14 facilities...
Antibody-dependent cell-mediated cytotoxicity (ADCC) has been suggested as an essential mechanism for the in vivo activity of cetuximab, epidermal growth factor receptor (EGFR)-targeting therapeutic antibody. Thus, enhancing affinity human IgG1 antibodies to natural killer (NK) cell-expressed FcγRIIIa by glyco- or protein-engineering their Fc portion demonstrated improve NK ADCC and represent a promising strategy antibody therapy. However, polymorphonuclear (PMN) effector cells express...
Efficacy of anticancer monoclonal antibodies (mAb) is limited by the exhaustion effector mechanisms. IgG mAbs mediate cellular functions through FcγRs expressed on cells. IgA can also induce efficient tumor killing both in vitro and vivo. recruit FcαRI-expressing cells therefore initiate different mechanisms vivo compared with IgG. Here, we studied coexpressing EGFR HER2 cetuximab trastuzumab their variants. In presence a heterogeneous population (leukocytes), combination to two targets...
Background: IgA constitutes a promising antibody isotype, which requires optimization before immunotherapeutic application.Results: P221R-mutated and wild type IgA2m(1) antibodies were similarly effective in killing tumor cells recruiting myeloid effector cells.Conclusion: Improved constitute next generation for therapy.Significance: These studies support the clinical development of therapeutic antibodies. application. Results: cells. Conclusion: therapy. Significance:
Oncogenic mutations of the KRAS gene have emerged as a common mechanism resistance against epidermal growth factor receptor (EGF-R)-directed tumor therapy. Mutated leads to ligand-independent activation signaling pathways downstream EGF-R. Thereby, direct effector mechanisms EGF-R antibodies, such blockade ligand binding and inhibition signaling, are bypassed. Thus, humanized variant approved antibody Cetuximab inhibited wild-type KRAS-expressing A431 cells, but did not inhibit KRAS-mutated...
ABSTRACT To date, no drugs are approved for BK polyomavirus (BKPyV) reactivation, a major cause of nephropathy after kidney transplantation. Recently, tumor necrosis factor‐α (TNF‐α) blockade has been proposed as promising therapy, however, the effect TNF‐α on clinically most common archetype (ww) BKPyV remained unclear. Assays in primary renal proximal tubule epithelial cells (RPTEC) allowed efficient replication only strains with rearranged (rr) non‐coding control regions (NCCR), which may...
// Matthias Peipp 1 , Stefanie Derer Stefan Lohse Staudinger Katja Klausz Thomas Valerius Martin Gramatzki Christian Kellner Division of Stem Cell Transplantation and Immunotherapy, 2 nd Department Medicine, Christian-Albrechts-University Kiel, Germany Correspondence to: Kellner, e-mail: c.kellner@med2.uni-kiel.de Keywords: NK cells, NKp30, NKp80, B7-H6, ADCC Received: November 17, 2014 Accepted: September 04, 2015 Published: 15, ABSTRACT cells detect tumors through activating surface...
Monoclonal antibodies (mAb) against variant III of epidermal growth factor receptor (EGFRvIII) hold promise for improving tumor selectivity EGFR-targeted therapy. Here, we compared Fc-mediated effector functions three mAb EGFRvIII (MR1-1, ch806, 13.1.2) with those zalutumumab, a high affinity EGFR in advanced clinical trials. MR1-1 and ch806 demonstrated preferential 13.1.2 exclusive binding to EGFRvIII, contrast which bound both wild-type EGFRvIII. All four human IgG1κ mediated...
Currently, no established biomarkers are recommended for the routine diagnosis of penile carcinoma (PeCa). The rising incidence this human papillomavirus (HPV)-related cancer entity highlights need promising candidates. Calprotectin subunits S100A8 and S100A9 mark myeloid-derived suppressor cells in other HPV-related entities while their receptor CD147 was discussed to identify patients with PeCa at a higher risk poor prognoses treatment failure. We thus examined expression using...